Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421343 · ClinicalTrials.gov registry record · Phase 3
Secondary Prevention of Osteoporosis
A Phase 3 study of Osteoporosis, sponsored by Hebrew SeniorLife.
- Completed
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00421343: Completed Phase 3 study of Osteoporosis, sponsored by Hebrew SeniorLife.
NCT00421343 is a Phase 3 study of Osteoporosis that has completed, run by Hebrew SeniorLife. The registered enrollment target is 29 participants, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421343, a Phase 3 study of Osteoporosis, has completed, sponsored by Hebrew SeniorLife.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.
Conditions Studied
Interventions
- DRUG alendronate with cholecalciferol
- DRUG calcium carbonate with cholecalciferol
- BEHAVIORAL Falls prevention measures
Study Locations (1)
Massachusetts
- Hebrew SeniorLife - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00421343 record still lists
NCT00421343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 3 interventions - of which alendronate with cholecalciferol is the first listed.
NCT00421343 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00421343 about?
NCT00421343 is a clinical study titled "Secondary Prevention of Osteoporosis". The purpose of this study is to develop and implement an evidence based protocol for the secondary prevention of osteoporotic fractures and falls, and to determine how compliance with this intervention improves muscle strength and functional status following a fracture.
What is the current status of trial NCT00421343?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2007-02. Estimated completion is 2008-06.
What conditions does trial NCT00421343 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00421343?
The interventions under investigation include: alendronate with cholecalciferol (DRUG), calcium carbonate with cholecalciferol (DRUG), Falls prevention measures (BEHAVIORAL).
Who is sponsoring clinical trial NCT00421343?
This trial is sponsored by Hebrew SeniorLife, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00421343 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00421343's enrollment target sits among peer trials
29 70th of 84 higher than 15 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
COMPLETED · Phase 3
-
HORIZON-PFT: Pivotal Fracture Trial
COMPLETED · Phase 3
-
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
COMPLETED · Phase 3
-
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia